A structured narrative review published in the Journal of Korean Medical Science concludes that the evidence does not support a single class-wide syndrome of ocular toxicity from glucagon-like peptide-1 receptor agonists. The authors do identify two signals worth watching, and they are specific rather than diffuse.

The drug class includes injectable semaglutide, sold as the Ozempic prefilled pen, which the review notes gained new national health insurance reimbursement criteria in Korea effective February 1, 2026. The authors frame proportionate ophthalmic preparedness as timely because use among eligible patients may expand, and they reviewed randomized trials, systematic reviews, large pharmacoepidemiologic studies, mechanistic work and regulatory assessments through June 30, 2026.

Why retinopathy worsens early

The most coherent retinal signal, according to the review, is early worsening of diabetic retinopathy during rapid glycemic improvement. That worsening is reported particularly in eyes that already carry substantial pre-existing disease, which makes it a question about the starting retina as much as about the drug.

This is the distinction the review keeps returning to, and it is a genuinely useful one. Available trial and real-world evidence, the authors write, does not demonstrate a uniform sustained toxic effect.

A rare optic nerve signal

Nonarteritic anterior ischemic optic neuropathy is described as a rare but clinically important semaglutide safety signal. Multiple observational studies and regulatory action justify vigilance, the authors say, although effect estimates remain heterogeneous and the absolute risk is low.

That is a carefully built sentence and worth reading as written. Heterogeneous estimates plus low absolute risk is not the same thing as a resolved question, and the review does not pretend otherwise.

Phenotype based monitoring

For retina specialists, the review recommends management based on phenotype: identify active or advanced diabetic retinopathy, avoid delaying indicated retinal treatment, document the timing and trajectory of metabolic change, and urgently evaluate sudden painless visual loss or field defects. The stated aim is to preserve the substantial systemic benefits of incretin therapy while improving recognition of uncommon but consequential ocular events.

Limitations

This is a narrative review rather than a meta-analysis, and the authors are explicit that effect estimates across the observational literature remain heterogeneous. Evidence for neovascular age-related macular degeneration is described as conflicting, while reported associations with retinal vein occlusion and glaucoma remain exploratory.

Bottom line

The review's position is that there is no single eye-toxicity syndrome here, but there are two signals that deserve named attention and several more that are not yet settled. What stays unresolved is how large the optic neuropathy risk actually is, and whether the macular degeneration signal survives better data.